Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco - 1 Dec 2007

David Sean P, Strong David R, Munafò Marcus R, Brown Richard A, Lloyd-Richardson Elizabeth E, Wileyto Paul E, Evins Eden A, Shields Peter G, Lerman Caryn, Niaura Raymond

Abstract excerpt

We analyzed pooled data from two comparable randomized placebo-controlled clinical trials of bupropion pharmacotherapy for smoking cessation for which data on DRD2 Taq1A genotype were available. A total of 722 smokers across the two trials were randomized to 10 weeks of sustained-release bupropion hydrochloride or placebo. General estimating equation analysis demonstrated a significant gene x drug interaction (B...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bupropion
Share to Confidence Intervals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopamine Uptake Inhibitors

Share to Double-Blind Method

Share to Randomized Controlled Trials as Topic

Share to Receptors, Dopamine D2

Share to Smoking Cessation

Share to Tobacco Use Disorder

Source

Open in PubMed Open full text

Identifiers

PMID: 18058343
DOI: 10.1080/14622200701705027
PMCID: PMC2128730

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.PMID 18058343Read ↗

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationSemantic proximity Read ↗

Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.Semantic proximity Read ↗

Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?Semantic proximity Read ↗

Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.Semantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers.Semantic proximity Read ↗

Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.Semantic proximity Read ↗

A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation.Semantic proximity Read ↗

Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.Semantic proximity Read ↗

Pharmacogenetic investigation of smoking cessation treatment.Semantic proximity Read ↗

No evidence for a major role of polymorphisms during bupropion treatment.Semantic proximity Read ↗

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.